Measures Summary, Fall 2014- eQOPI Submission

Measures Summary, Fall 2014- eQOPI Submission
QCDR (For CMS Reporting)
Module
#
Measure
QCDR
1
Staging documented within one month of first office visit (NQF 386)
NQS Domain: Effective Clinical Care (Process)
QCDR
2
Pain intensity quantified by second office visit (NQF 384)
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Process)
QCDR
3
Chemotherapy intent documented
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Process)
QCDR
4
Performance status documented prior to initiating non-curative chemotherapy regimen
NQS Domain: Efficiency and Cost Reduction (Process)
QCDR
5
Chemotherapy administered to patients with metastatic solid tumors and performance
status of 3, 4, or undocumented (Lower Score – Better)
NQS Domain: Efficiency and Cost Reduction (Process)
QCDR
6
Smoking status/tobacco use documented in past year * (NQF 0028 (adapted))
NQS Domain: Community/Population Health (Process)
QCDR
7
Antiemetic therapy prescribed for highly emetogenic chemotherapy
NQS Domain: Effective Clinical Care (Process)
QCDR
8
Antiemetic therapy prescribed for moderately emetogenic chemotherapy
NQS Domain: Effective Clinical Care (Process)
QCDR
9
QCDR
10
Pain intensity quantified on either of the last two visits before death (includes
documentation of no pain)
(NQF 0383/0384 (adapted))
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Process)
Hospice enrollment and enrolled more than 3 days before death (NQF 216)
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Outcome)
QCDR
11
Combination chemotherapy received within 4 months of diagnosis by women under 70 with
AJCC stage I (T1c) to III ER/PR negative breast cancer (NQF 559)
NQS Domain: Effective Clinical Care (Process)
QCDR
12
Test for Her2/neu overexpression or gene amplification (NQF 1878)
NQS Domain: Effective Clinical Care (Process)
QCDR
13
QCDR
14
Trastuzumab received by patients with AJCC stage I (T1c) to III Her2/neu positive breast
cancer (NQF 1858)
NQS Domain: Effective Clinical Care (Process)
Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage I (T1c) to III
ER or PR positive breast cancer (NQF 387)
NQS Domain: Effective Clinical Care (Process)
QCDR
15
GCSF administered to patients who received chemotherapy for metastatic cancer
(Lower Score – Better)
NQS Domain: Efficiency and Cost Reduction (Process)
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
Page 1 of 4
QOPI® Measures Summary, Fall 2014 – eQOPI Submission
QCDR
16
Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage
III colon cancer (NQF 385)
NQS Domain: Effective Clinical Care (Process)
Location of death documented (*paired measure) NQS Domain: Effective Clinical Care
(Process)
NQS Domain: Effective Clinical Care (Process)
Death from cancer in intensive care unit (*paired measure)
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Outcome)
QCDR
17
QCDR
18
QCDR
19
Chemotherapy administered within last 2 weeks of life (NQF 210)
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Process)
QCDR
20
Documentation of patient's advance directives by the third office visit (NQF 326)
NQS Domain: Person and Caregiver-Centered Experience and Outcomes (Process)
QOPI Certification Program (QCP) Measures – Pilot test for Fall14
Pathology report confirming malignancy*
Oncology cancer stage documented*
(NQF 0386 (adapted))
Core
Core
1
2
Core
6
Pain addressed appropriately (defect-free measure, 3, 4a, and 5)*
(NQF 0383/0384 (adapted))
Core
Core
Core
9
10
21a
Documented plan for chemotherapy, including doses, route, and time intervals*
Chemotherapy intent (curative vs palliative) documented*
Smoking status/tobacco use documented in past year *
(NQF 0028 (adapted))
Core
Symptom
24
27
Symptom
EOL
33
38
Patient emotional well-being assessed by the second office visit*
Corticosteroids and serotonin antagonist prescribed with moderate/high emetic risk
chemotherapy*
Infertility risks discussed prior to chemotherapy with patients of reproductive age*
Pain addressed appropriately (defect-free measure, 35, 36a, and 37)*
(NQF 0383/0384 (adapted))
EOL
45a
Breast
53
Breast
54
Test for Her-2/neu overexpression or gene amplification*
(NQF 1878 (adapted))
Breast
56a
Trastuzumab not received when Her-2/neu is negative or undocumented (inverse of 56 )*
(NQF 1857 (adapted))
Breast
57
Trastuzumab received by patients with AJCC stage I (T1c) to III Her-2/neu positive breast
cancer
(NQF 1858 (adapted))
Hospice enrollment and enrolled more than 7 days before death (defect-free measure, 42
and inverse 45)*
(NQF 0216 (adapted))
Combination chemotherapy received within 4 months of diagnosis by women under 70 with
AJCC stage I (T1c) to III ER/PR negative breast cance
(NQF 0559 (adapted))
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
Page 2 of 4
QOPI® Measures Summary, Fall 2014 – eQOPI Submission
Breast
59
Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage I (T1c) to III
ER or PR positive breast cancer
(NQF 0220/0387 (adapted))
Colorectal 66
Colorectal 68
CEA within 4 months of curative resection for colorectal cancer*
Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage
III colon cancer
(NQF 0223/0385 (adapted))
Adjuvant chemotherapy received within 9 months of diagnosis by patients with AJCC stage
II or III rectal cancer
Colonoscopy before or within 6 months of curative colorectal resection or completion of
primary adjuvant chemotherapy*
(NQF 0572 (adapted))
Colorectal 72
Colorectal 73
Colorectal 74
KRAS testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb
therapy*(NQF 1859 (adapted))
Colorectal 75a
Anti-EGFR MoAb therapy not received by patients with KRAS mutation (Inverse of 75 )*
(NQF 1860 (adapted))
NSCLC
81
Adjuvant cisplatin-based chemotherapy received within 60 days after curative resection by
patients with AJCC stage II or IIIA NSCLC
NSCLC
84
NSCLC
85
Performance status documented for patients with initial AJCC stage IV or distant metastatic
NSCLC*
Platinum doublet first-line chemotherapy or EGFR-TKI (or other targeted therapy with
documented DNA mutation) received by patients with initial AJCC stage IV or distant
metastatic NSCLC with performance status of 0-1 without prior history of chemotherapy*
NSCLC
88
Core
6b
Core
Core
25b
25c
Core
25d
Core
25e
EOL
EOL
42
47b1
EOL
47c1
Percentage of patients with invasive malignancy who died in known location: ICU without
hospice/palliative care (Test Measure)
Breast
52a
Breast
60
Complete staging for women with invasive breast cancer (Cancer stage, HER2,and ER/PR
status)
Tamoxifen or AI received when ER/PR status is negative or undocumented
(Lower Score – Better)
Positive mutation for patients with stage IV NSCLC who received first-line EGFR tyrosine
kinase inhibitor or other targeted therapy*
General eQOPI Measures
Pain intensity quantified on either of the two most recent office visits
(NQF 0383/0384 (adapted))
Height, weight, and BSA documented prior to curative chemotherapy
Performance status documented during every clinic visit for patients with
advanced/metastatic disease during past 12 months
Pain intensity quantified during every clinic visit for patients with advanced/metastatic
disease during past 12 months
GCSF administered to patients who received chemotherapy for metastatic cancer
(Lower Score - Better)
Hospice enrollment (NQF 0215 (adapted))
Percentage of patients with invasive malignancy who died in known location: licensed
hospital without hospice/palliative care (Test Measure)
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
Page 3 of 4
QOPI® Measures Summary, Fall 2014 – eQOPI Submission
Breast
62d
GCSF administered to patients who received chemotherapy for metastatic breast cancer
(Lower Score - Better) (Test Measure - Top 5)
Colorectal 75b
GCSF administered to patients who received chemotherapy for metastatic colon cancer
(Lower Score - Better) (Test Measure - Top 5)
NSCLC
NSCLC
80
86a
Adjuvant chemotherapy received by patients with AJCC stage II or IIIA NSCLC
Bevacizumab received by patients with initial AJCC stage IV or distant metastatic NSCLC
with squamous histology (Lower Score - Better)
NSCLC
89
First-line EGFR tyrosine kinase inhibitor or other targeted therapy received by patients with
stage IV NSCLC in the absence of positive mutation (Lower Score - Better)
NSCLC
89a
GCSF administered to patients who received chemotherapy for metastatic NSCLC cancer
(Lower Score - Better) (Test Measure - Top 5)
*Included in QOPI Certification overall quality score
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
Page 4 of 4

Download Report